Contribution of the immune system to bystander and non-targeted effects of ionizing radiation

Cancer Letters

Volumn 356, Issue 1, 2015, Pages 105-113

  Rödel, Franz ^a   Frey, Benjamin ^b   Multhoff, Gabriele ^c   Gaipl, Udo ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Abscopal effect; Bystander effects; Heat shock protein 70; Immune system; Ionizing radiation; Non targeted effects

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; PROTEIN P53; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; X LINKED INHIBITOR OF APOPTOSIS; ANTIINFLAMMATORY AGENT; CYTOKINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MICRORNA;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BYSTANDER EFFECT; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL FUNCTION; CELL INFILTRATION; DENDRITIC CELL; GENETIC CONSERVATION; HISTONE MODIFICATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; IONIZING RADIATION; LEUKOCYTE; MACROPHAGE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIATION DOSE; RADIATION PROTECTION; RADIOBIOLOGY; RNA INTERFERENCE; SHORT SURVEY; T LYMPHOCYTE; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL NUCLEUS; CYTOTOXIC T LYMPHOCYTE; GENOMIC INSTABILITY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MOUSE; NEOPLASM; RADIATION RESPONSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BYSTANDER EFFECT; CELL NUCLEUS; CYTOKINES; DENDRITIC CELLS; GENOMIC INSTABILITY; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84912524142     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.015     Document Type: Review

References (146)

1. Shiraishi K., Ishiwata Y., Nakagawa K., Yokochi S., Taruki C., Akuta T., Ohtomo K., Matsushima K., Tamatani T., Kanegasaki S. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin. Cancer Res. 2008, 14:1159-1166.
2. Hei T.K., Zhou H., Chai Y., Ponnaiya B., Ivanov V.N. Radiation induced non-targeted response: mechanism and potential clinical implications. Curr. Mol. Pharmacol. 2011, 4:96-105.
3. Mothersill C., Seymour C. Radiation-induced non-targeted effects of low doses-what, why and how?. Health Phys. 2011, 100:302.
4. Barcellos-Hoff M.H. How tissues respond to damage at the cellular level: orchestration by transforming growth factor-{beta} (TGF-{beta}). BJR Suppl. 2005, 27:123-127.
5. Belyakov O.V., Mitchell S.A., Parikh D., Randers-Pehrson G., Marino S.A., Amundson S.A., Geard C.R., Brenner D.J. Biological effects in unirradiated human tissue induced by radiation damage up to 1mm away. Proc. Natl. Acad. Sci. USA 2005, 102:14203-14208.
6. Bertucci A., Pocock R.D., Randers-Pehrson G., Brenner D.J. Microbeam irradiation of the C. elegans nematode. J. Radiat. Res. 2009, 50(Suppl. A):A49-A54.
7. Williams J., Chen Y., Rubin P., Finkelstein J., Okunieff P. The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003, 13:182-188.
8. Seegenschmiedt M.H., Makoski H.B., Trott K.R., Brady L.W.E. Radiotherapy for Non-Malignant Disorders 2008, Springer Verlag, Berlin, Heidelberg.
9. Rodel F., Frey B., Gaipl U., Keilholz L., Fournier C., Manda K., Schollnberger H., Hildebrandt G., Rodel C. Modulation of inflammatory immune reactions by low-dose ionizing radiation: molecular mechanisms and clinical application. Curr. Med. Chem. 2012, 19:1741-1750.
10. Solokoff Röntgenstrahlen gegen Gelenkrheumatismus. Wien. Med. Wochenschr. 1898, 570.
11. Seegenschmiedt M.H., Micke O., Willich N. Radiation therapy for nonmalignant diseases in Germany. Current concepts and future perspectives. Strahlenther. Onkol. 2004, 180:718-730.
12. Cannon B., Randolph J.G., Murray J.E. Malignant irradiation for benign conditions. N. Engl. J. Med. 1959, 260:197-202.
13. Brown W.M., Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br. Med. J. 1965, 2:1327-1332.
14. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 2007, 42:3-27.
15. Adamietz B., Schulz-Wendtland R., Alibek S., Uder M., Sauer R., Ott O., Keilholz L. Calcifying tendonitis of the shoulder joint: predictive value of pretreatment sonography for the response to low-dose radiotherapy. Strahlenther. Onkol. 2010, 186:18-23.
16. Ott O.J., Hertel S., Gaipl U.S., Frey B., Schmidt M., Fietkau R. Benign painful shoulder syndrome: initial results of a single-center prospective randomized radiotherapy dose-optimization trial. Strahlenther. Onkol. 2012, 188:1108-1113.
17. Ott O.J., Hertel S., Gaipl U.S., Frey B., Schmidt M., Fietkau R. Benign painful elbow syndrome. First results of a single center prospective randomized radiotherapy dose optimization trial. Strahlenther. Onkol. 2012, 188:873-877.
18. Kobayashi S.D., Voyich J.M., Burlak C., DeLeo F.R. Neutrophils in the innate immune response. Arch. Immunol. Ther. Exp. (Warsz) 2005, 53:505-517.
19. Valledor A.F., Comalada M., Santamaria-Babi L.F., Lloberas J., Celada A. Macrophage proinflammatory activation and deactivation: a question of balance. Adv. Immunol. 2010, 108:1-20.
20. Fujiwara N., Kobayashi K. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 2005, 4:281-286.
21. Abramson S.B., Attur M., Amin A.R., Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr. Rheumatol. Rep. 2001, 3:535-541.
22. Hildebrandt G., Seed M.P., Freemantle C.N., Alam C.A., Colville-Nash P.R., Trott K.R. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. Int. J. Radiat. Biol. 1998, 74:367-378.
23. Schaue D., Jahns J., Hildebrandt G., Trott K.R. Radiation treatment of acute inflammation in mice. Int. J. Radiat. Biol. 2005, 81:657-667.
24. Mosmann T.R. Properties and functions of interleukin-10. Adv. Immunol. 1994, 56:1-26.
25. Dinarello C.A. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur. J. Immunol. 2011, 41:1203-1217.
26. Baggiolini M., Loetscher P. Chemokines in inflammation and immunity. Immunol. Today 2000, 21:418-420.
27. Tsukimoto M., Homma T., Mutou Y., Kojima S. 0.5Gy gamma radiation suppresses production of TNF-alpha through up-regulation of MKP-1 in mouse macrophage RAW264.7 cells. Radiat. Res. 2009, 171:219-224.
28. Frischholz B., Wunderlich R., Ruhle P.F., Schorn C., Rodel F., Keilholz L., Fietkau R., Gaipl U.S., Frey B. Reduced secretion of the inflammatory cytokine IL-1beta by stimulated peritoneal macrophages of radiosensitive Balb/c mice after exposure to 0.5 or 0.7Gy of ionizing radiation. Autoimmunity 2013.
29. Sampson A.P. The role of eosinophils and neutrophils in inflammation. Clin. Exp. Allergy 2000, 30(Suppl. 1):22-27.
30. Scapini P., Lapinet-Vera J.A., Gasperini S., Calzetti F., Bazzoni F., Cassatella M.A. The neutrophil as a cellular source of chemokines. Immunol. Rev. 2000, 177:195-203.
31. Rodel F., Hofmann D., Auer J., Keilholz L., Rollinghoff M., Sauer R., Beuscher H.U. The anti-inflammatory effect of low-dose radiation therapy involves a diminished CCL20 chemokine expression and granulocyte/endothelial cell adhesion. Strahlenther. Onkol. 2008, 184:41-47.
32. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
33. Voll R.E., Herrmann M., Roth E.A., Stach C., Kalden J.R., Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997, 390:350-351.
34. Kern P., Keilholz L., Forster C., Seegenschmiedt M.H., Sauer R., Herrmann M. In vitro apoptosis in peripheral blood mononuclear cells induced by low-dose radiotherapy displays a discontinuous dose-dependence. Int. J. Radiat. Biol. 1999, 75:995-1003.
35. Kern P.M., Keilholz L., Forster C., Stach C., Beyer T.D., Gaipl U.S., Kalden J.R., Hallmann R., Herrmann M. UVB-irradiated T-cells undergoing apoptosis lose L-selectin by metalloprotese-mediated shedding. Int. J. Radiat. Biol. 2000, 76:1265-1271.
36. Belloni P., Latini P., Palitti F. Radiation-induced bystander effect in healthy G(o) human lymphocytes: biological and clinical significance. Mutat. Res. 2011, 713:32-38.
37. Gaipl U.S., Meister S., Lodermann B., Rodel F., Fietkau R., Herrmann M., Kern P.M., Frey B. Activation-induced cell death and total Akt content of granulocytes show a biphasic course after low-dose radiation. Autoimmunity 2009, 42:340-342.
38. Yang Z.Z., Tschopp O., Baudry A., Dummler B., Hynx D., Hemmings B.A. Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans. 2004, 32:350-354.
39. Rastogi S., Boylan M., Wright E.G., Coates P.J. Interactions of apoptotic cells with macrophages in radiation-induced bystander signaling. Radiat. Res. 2013, 179:135-145.
40. Speyer C.L., Ward P.A. Role of endothelial chemokines and their receptors during inflammation. J. Invest. Surg. 2011, 24:18-27.
41. Kern P.M., Keilholz L., Forster C., Hallmann R., Herrmann M., Seegenschmiedt M.H. Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. Radiother. Oncol. 2000, 54:273-282.
42. Roedel F., Kley N., Beuscher H.U., Hildebrandt G., Keilholz L., Kern P., Voll R., Herrmann M., Sauer R. Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion. Int. J. Radiat. Biol. 2002, 78:711-719.
43. Hildebrandt G., Maggiorella L., Rodel F., Rodel V., Willis D., Trott K.R. Mononuclear cell adhesion and cell adhesion molecule liberation after X-irradiation of activated endothelial cells in vitro. Int. J. Radiat. Biol. 2002, 78:315-325.
44. Arenas M., Gil F., Gironella M., Hernandez V., Jorcano S., Biete A., Pique J.M., Panes J. Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:560-567.
45. Habraken Y., Piette J. NF-kappaB activation by double-strand breaks. Biochem. Pharmacol. 2006, 72:1132-1141.
46. Magne N., Toillon R.A., Bottero V., Didelot C., Houtte P.V., Gerard J.P., Peyron J.F. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 2006, 231:158-168.
47. Prasad A.V., Mohan N., Chandrasekar B., Meltz M.L. Induction of transcription of "immediate early genes" by low-dose ionizing radiation. Radiat. Res. 1995, 143:263-272.
48. Prasad A.V., Mohan N., Chandrasekar B., Meltz M.L. Activation of nuclear factor kappa B in human lymphoblastoid cells by low-dose ionizing radiation. Radiat. Res. 1994, 138:367-372.
49. Rodel F., Hantschel M., Hildebrandt G., Schultze-Mosgau S., Rodel C., Herrmann M., Sauer R., Voll R.E. Dose-dependent biphasic induction and transcriptional activity of nuclear factor kappa B (NF-kappaB) in EA.hy.926 endothelial cells after low-dose X-irradiation. Int. J. Radiat. Biol. 2004, 80:115-123.
50. Hofer-Warbinek R., Schmid J.A., Stehlik C., Binder B.R., Lipp J., de Martin R. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J. Biol. Chem. 2000, 275:22064-22068.
51. Jin H.S., Lee D.H., Kim D.H., Chung J.H., Lee S.J., Lee T.H. CIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res. 2009, 69:1782-1791.
52. Rodel F., Frey B., Capalbo G., Gaipl U., Keilholz L., Voll R., Hildebrandt G., Rodel C. Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF-kappaB activation and mediates the anti-inflammatory properties of low-dose ionising-radiation. Radiother. Oncol. 2010, 97:346-351.
53. Criswell T., Leskov K., Miyamoto S., Luo G., Boothman D.A. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003, 22:5813-5827.
54. Rodel F., Keilholz L., Herrmann M., Weiss C., Frey B., Voll R., Gaipl U., Rodel C. Activator protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. Autoimmunity 2009, 42:343-345.
55. Martin L.M., Marples B., Lynch T.H., Hollywood D., Marignol L. Exposure to low dose ionising radiation: molecular and clinical consequences. Cancer Lett 2013, 338:209-218.
56. Ma S., Liu X., Jiao B., Yang Y. Low-dose radiation-induced responses: focusing on epigenetic regulation. Int. J. Radiat. Biol. 2010, 86:517-528.
57. Pajonk F., McBride W.H. Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses. Radiother. Oncol. 2001, 59:203-212.
58. Pluder F., Barjaktarovic Z., Azimzadeh O., Mortl S., Kramer A., Steininger S., Sarioglu H., Leszczynski D., Nylund R., Hakanen A., Sriharshan A., Atkinson M.J., Tapio S. Low-dose irradiation causes rapid alterations to the proteome of the human endothelial cell line EA.hy926. Radiat. Environ. Biophys. 2011, 50:155-166.
59. Ranjha R., Paul J. Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm. Res. 2013, 62:343-355.
60. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
61. Kraemer A., Anastasov N., Angermeier M., Winkler K., Atkinson M.J., Moertl S. MicroRNA-mediated processes are essential for the cellular radiation response. Radiat. Res. 2011, 176:575-586.
62. Voellenkle C., Rooij J., Guffanti A., Brini E., Fasanaro P., Isaia E., Croft L., David M., Capogrossi M.C., Moles A., Felsani A., Martelli F. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA 2012, 18:472-484.
63. Chaudhry M.A., Omaruddin R.A. Differential regulation of microRNA expression in irradiated and bystander cells. Mol. Biol. (Mosk) 2012, 46:634-643.
64. Barjaktarovic Z., Anastasov N., Azimzadeh O., Sriharshan A., Sarioglu H., Ueffing M., Tammio H., Hakanen A., Leszczynski D., Atkinson M.J., Tapio S. Integrative proteomic and microRNA analysis of primary human coronary artery endothelial cells exposed to low-dose gamma radiation. Radiat. Environ. Biophys. 2013, 52:87-98.
65. Hu B., Elinav E., Huber S., Booth C.J., Strowig T., Jin C., Eisenbarth S.C., Flavell R.A. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. USA 2010, 107:21635-21640.
66. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J.L., Schlemmer F., Tasdemir E., Uhl M., Genin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., Andre F., Lidereau R., McLaughlin N.M., Haynes N.M., Smyth M.J., Kroemer G., Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
67. Mole R.H. Whole body irradiation; radiobiology or medicine?. Br. J. Radiol. 1953, 26:234-241.
68. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
69. Frey B., Rubner Y., Wunderlich R., Weiss E.M., Pockley A.G., Fietkau R., Gaipl U.S. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr. Med. Chem. 2012, 19:1751-1764.
70. Rubner Y., Wunderlich R., Ruhle P.F., Kulzer L., Werthmoller N., Frey B., Weiss E.M., Keilholz L., Fietkau R., Gaipl U.S. How does ionizing irradiation contribute to the induction of anti-tumor immunity?. Front. Oncol. 2012, 2:75.
71. Lauber K., Ernst A., Orth M., Herrmann M., Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front. Oncol. 2012, 2:116.
72. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., Formenti S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:862-870.
73. Kim K.W., Kim S.H., Shin J.G., Kim G.S., Son Y.O., Park S.W., Kwon B.H., Kim D.W., Lee C.H., Sol M.Y., Jeong M.H., Chung B.S., Kang C.D. Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int. J. Cancer 2004, 109:685-690.
74. Park Y.S., Bae J.H., Son C.H., Lee K.S., Kim W., Jung M.H., Yang K., Kim S.H., Kang C.D. Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor. Immunol. Invest. 2011, 40:383-399.
75. Takeshima T., Chamoto K., Wakita D., Ohkuri T., Togashi Y., Shirato H., Kitamura H., Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010, 70:2697-2706.
76. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 2005, 174:7516-7523.
77. Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., Fu Y.X., Auh S.L. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
78. Lugade A.A., Sorensen E.W., Gerber S.A., Moran J.P., Frelinger J.G., Lord E.M. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J. Immunol. 2008, 180:3132-3139.
79. Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., Beckett M., Sharma R., Chin R., Tu T., Weichselbaum R.R., Fu Y.X. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
80. Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., Schreiber H., You Z., Kaynor C., Wang X., Fu Y.X. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol. 2007, 179:1960-1968.
81. Everse L.A., Renes I.B., Jurgenliemk-Schulz I.M., Rutgers D.H., Bernsen M.R., Dullens H.F., Den Otter W., Battermann J.J. Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. Int. J. Cancer 1997, 72:1003-1007.
82. Schildkopf P., Frey B., Ott O.J., Rubner Y., Multhoff G., Sauer R., Fietkau R., Gaipl U.S. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. Radiother. Oncol. 2011, 101:109-115.
83. Aymeric L., Apetoh L., Ghiringhelli F., Tesniere A., Martins I., Kroemer G., Smyth M.J., Zitvogel L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010, 70:855-858.
84. Frey B., Stache C., Rubner Y., Werthmoller N., Schulz K., Sieber R., Semrau S., Rodel F., Fietkau R., Gaipl U.S. Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential. J. Immunotoxicol. 2012, 9:301-313.
85. G. Multhoff, Heat shock proteins in immunity, in: Handbook of Experimental Pharmacology, 2006, p. 25.
86. Multhoff G., Rodel F., Pockley A.G., Gaipl U.S. Frontiers research topic: radiation-induced effects and the immune system. Front. Oncol. 2013, 3:55.
87. Ohba K., Omagari K., Nakamura T., Ikuno N., Saeki S., Matsuo I., Kinoshita H., Masuda J., Hazama H., Sakamoto I., Kohno S. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998, 43:575-577.
88. Okuma K., Yamashita H., Niibe Y., Hayakawa K., Nakagawa K. Abscopal effect of radiation on lung metastases of hepatocellular carcinoma: a case report. J. Med. Case Rep. 2011, 5:111.
89. Wersall P.J., Blomgren H., Pisa P., Lax I., Kalkner K.M., Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006, 45:493-497.
90. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013, 14:e218-e228.
91. Antoniades J., Brady L.W., Lightfoot D.A. Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 1977, 2:141-147.
92. Konoeda K. Therapeutic efficacy of pre-operative radiotherapy on breast carcinoma: in special reference to its abscopal effect on metastatic lymph-nodes. Nihon Gan Chiryo Gakkai Shi 1990, 25:1204-1214.
93. Isobe Y., Aritaka N., Sasaki M., Oshimi K., Sugimoto K. Spontaneous regression of natural killer cell lymphoma. J. Clin. Pathol. 2009, 62:647-650.
94. Kingsley D.P. An interesting case of possible abscopal effect in malignant melanoma. Br. J. Radiol. 1975, 48:863-866.
95. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., Sedrak C., Jungbluth A.A., Chua R., Yang A.S., Roman R.A., Rosner S., Benson B., Allison J.P., Lesokhin A.M., Gnjatic S., Wolchok J.D. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366:925-931.
96. Molls M., Vaupel P., Nieder C., Anscher M. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies 2009, Springer, Berlin, Heidelberg.
97. Lindquist S., Craig E.A. The heat-shock proteins. Annu. Rev. Genet. 1988, 22:631-677.
98. DeNagel D.C., Pierce S.K. A case for chaperones in antigen processing. Immunol. Today 1992, 13:86-89.
99. Shamovsky I., Nudler E. New insights into the mechanism of heat shock response activation. Cell. Mol. Life Sci. 2008, 65:855-861.
100. Pirkkala L., Nykanen P., Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J. 2001, 15:1118-1131.
101. Akerfelt M., Morimoto R.I., Sistonen L. Heat shock factors: integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 2010, 11:545-555.
102. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
103. Ciocca D.R., Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperon. 2005, 10:86-103.
104. Calderwood S.K., Gong J. Molecular chaperones in mammary cancer growth and breast tumor therapy. J. Cell. Biochem. 2012, 113:1096-1103.
105. Murshid A., Gong J., Stevenson M.A., Calderwood S.K. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev. Vaccines 2011, 10:1553-1568.
106. Calderwood S.K. Heat shock proteins in breast cancer progression - a suitable case for treatment?. Int. J. Hyperther. 2010, 26:681-685.
107. Neckers L., Lee Y.S. Cancer: the rules of attraction. Nature 2003, 425:357-359.
108. Khaleque M.A., Bharti A., Sawyer D., Gong J., Benjamin I.J., Stevenson M.A., Calderwood S.K. Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene 2005, 24:6564-6573.
109. Hartl F.U. Molecular chaperones in cellular protein folding. Nature 1996, 381:571-579.
110. Shin B.K., Wang H., Yim A.M., Le Naour F., Brichory F., Jang J.H., Zhao R., Puravs E., Tra J., Michael C.W., Misek D.E., Hanash S.M. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 2003, 278:7607-7616.
111. Stangl S., Gehrmann M., Riegger J., Kuhs K., Riederer I., Sievert W., Hube K., Mocikat R., Dressel R., Kremmer E., Pockley A.G., Friedrich L., Vigh L., Skerra A., Multhoff G. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc. Natl. Acad. Sci. USA 2011, 108:733-738.
112. Multhoff G., Botzler C., Wiesnet M., Eissner G., Issels R. CD3- large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood 1995, 86:1374-1382.
113. Multhoff G., Botzler C., Wiesnet M., Muller E., Meier T., Wilmanns W., Issels R.D. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int. J. Cancer 1995, 61:272-279.
114. Chen X., Tao Q., Yu H., Zhang L., Cao X. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol. Lett. 2002, 84:81-87.
115. Goloudina A.R., Demidov O.N., Garrido C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett. 2012, 325:117-124.
116. Multhoff G., Pfister K., Botzler C., Jordan A., Scholz R., Schmetzer H., Burgstahler R., Hiddemann W. Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors. Int. J. Cancer 2000, 88:791-797.
117. Stangl S., Wortmann A., Guertler U., Multhoff G. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J. Immunol. 2006, 176:6270-6276.
118. Pfister K., Radons J., Busch R., Tidball J.G., Pfeifer M., Freitag L., Feldmann H.J., Milani V., Issels R., Multhoff G. Patient survival by Hsp70 membrane phenotype: association with different routes of metastasis. Cancer 2007, 110:926-935.
119. Gehrmann M., Schmetzer H., Eissner G., Haferlach T., Hiddemann W., Multhoff G. Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica 2003, 88:474-476.
120. Gehrmann M., Liebisch G., Schmitz G., Anderson R., Steinem C., De Maio A., Pockley G., Multhoff G. Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS One 2008, 3:e1925.
121. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39:93-98.
122. Multhoff G., Botzler C., Jennen L., Schmidt J., Ellwart J., Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol. 1997, 158:4341-4350.
123. Multhoff G., Pfister K., Gehrmann M., Hantschel M., Gross C., Hafner M., Hiddemann W. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperon. 2001, 6:337-344.
124. Gross C., Koelch W., DeMaio A., Arispe N., Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J. Biol. Chem. 2003, 278:41173-41181.
125. Gross C., Hansch D., Gastpar R., Multhoff G. Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol. Chem. 2003, 384:267-279.
126. Gross C., Schmidt-Wolf I.G., Nagaraj S., Gastpar R., Ellwart J., Kunz-Schughart L.A., Multhoff G. Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperon. 2003, 8:348-360.
127. Multhoff G., Mizzen L., Winchester C.C., Milner C.M., Wenk S., Eissner G., Kampinga H.H., Laumbacher B., Johnson J. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp. Hematol. 1999, 27:1627-1636.
128. Gastpar R., Gross C., Rossbacher L., Ellwart J., Riegger J., Multhoff G. The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J. Immunol. 2004, 172:972-980.
129. Botzler C., Schmidt J., Luz A., Jennen L., Issels R., Multhoff G. Differential Hsp70 plasma-membrane expression on primary human tumors and metastases in mice with severe combined immunodeficiency. Int. J. Cancer 1998, 77:942-948.
130. Moser C., Schmidbauer C., Gurtler U., Gross C., Gehrmann M., Thonigs G., Pfister K., Multhoff G. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells. Cell Stress Chaperon. 2002, 7:365-373.
131. Krause S.W., Gastpar R., Andreesen R., Gross C., Ullrich H., Thonigs G., Pfister K., Multhoff G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin. Cancer Res. 2004, 10:3699-3707.
132. Yasumura S., Lin W.C., Hirabayashi H., Vujanovic N.L., Herberman R.B., Whiteside T.L. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. Cancer Res. 1994, 54:3808-3816.
133. Vujanovic N.L., Yasumura S., Hirabayashi H., Lin W.C., Watkins S., Herberman R.B., Whiteside T.L. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J. Immunol. 1995, 154:281-289.
134. Whiteside T.L., Vujanovic N.L., Herberman R.B. Natural killer cells and tumor therapy. Curr. Top. Microbiol. Immunol. 1998, 230:221-244.
135. Triantafilou M., Triantafilou K. Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide. Biochem. Soc. Trans. 2004, 32:636-639.
136. Wheeler D.S., Chase M.A., Senft A.P., Poynter S.E., Wong H.R., Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respir. Res. 2009, 10:31.
137. Matzinger P. An innate sense of danger. Semin. Immunol. 1998, 10:399-415.
138. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
139. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007, 81:1-5.
140. Asea A., Kraeft S.K., Kurt-Jones E.A., Stevenson M.A., Chen L.B., Finberg R.W., Koo G.C., Calderwood S.K. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 2000, 6:435-442.
141. Asea A., Rehli M., Kabingu E., Boch J.A., Bare O., Auron P.E., Stevenson M.A., Calderwood S.K. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 2002, 277:15028-15034.
142. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr. Opin. Pharmacol. 2009, 9:351-369.
143. Chase M.A., Wheeler D.S., Lierl K.M., Hughes V.S., Wong H.R., Page K. Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4- and NF-kappaB-dependent mechanism. J. Immunol. 2007, 179:6318-6324.
144. Paduch R., Jakubowicz-Gil J., Kandefer-Szerszen M. Expression of HSP27, HSP72 and MRP proteins in in vitro co-culture of colon tumour cell spheroids with normal cells after incubation with rhTGF- beta1 and/or CPT-11. J. Biosci. 2009, 34:927-940.
145. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
146. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.